GRANGE DAVID L 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Jun 18, 2010
Insider Transaction Report
Form 4
GRANGE DAVID L
DirectorChief Executive Officer
Transactions
- Award
Stock Options (to buy)
2010-06-17+50,000→ 50,000 totalExercise: $26.64From: 2011-06-17Exp: 2020-06-17→ Common Stock (50,000 underlying)
Holdings
- 103,506
Stock Options (to buy)
Exercise: $20.45From: 2011-02-25Exp: 2020-02-25→ Common Stock (103,506 underlying) - 6,485
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying) - 61,045
Common Stock
- 207,012
Stock Options (to buy)
Exercise: $21.98From: 2010-07-01Exp: 2019-07-01→ Common Stock (207,012 underlying)
Footnotes (5)
- [F1]50,000 shares of restricted stock were granted upon the Reporting Person's acceptance of employment as Chief Executive Officer. These shares vest in four equal increments on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.
- [F2]The options vest in three equal installments on 6/17/11, 6/17/12 and 6/17/13.
- [F3]Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.
- [F4]The options vest in three equal installments on 2/25/11, 2/25/12 and 2/25/13.
- [F5]The options vest in four equal installments of 50,000 on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.